Search

Your search keyword '"antineoplastic drugs"' showing total 2,253 results

Search Constraints

Start Over You searched for: Descriptor "antineoplastic drugs" Remove constraint Descriptor: "antineoplastic drugs"
2,253 results on '"antineoplastic drugs"'

Search Results

1. Cytotoxic activity of callus extract from Vachellia farnesiana (L) Wight & Arn.

2. Evaluation of Different Wipes’ Performance for Sampling the Antineoplastic Drug 5-Fluorouracil from Various Surfaces

3. Looking into the thermostable archaeal l-asparaginases.

4. Personal Protective Equipment Use and Surface Contamination With Antineoplastic Drugs: The Impact of the COVID-19 Pandemic.

5. CCL2 and Lactate from Chemotherapeutics-Treated Fibroblasts Drive Malignant Traits by Metabolic Rewiring in Low-Migrating Breast Cancer Cell Lines.

6. 肿瘤合并慢性肾脏病患者抗肿瘤治疗药物 用药指导中国专家共识 (2024版).

8. Therapeutic drug monitoring guidelines in oncology: what do we know and how to move forward? Insights from a systematic review.

9. The application of Global Trigger Tool in monitoring antineoplastic adverse drug events: a retrospective study.

10. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.

11. The Comet Assay as a Tool in Human Biomonitoring Studies of Environmental and Occupational Exposure to Chemicals—A Systematic Scoping Review.

12. Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.

13. Exposure Assessment and Monitoring of Antiblastic Drugs Preparation in Health Care Settings: A Systematic Review.

14. A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5.

15. An Automated Micro Solid-Phase Extraction (μSPE) Liquid Chromatography-Mass Spectrometry Method for Cyclophosphamide and Iphosphamide: Biological Monitoring in Antineoplastic Drug (AD) Occupational Exposure.

16. Anticancer drugs are the first cause of drug- induced liver injury in a reference hospital.

17. 基于双重差分模型的药品集中采购对 某院抗肿瘤药使用的影响.

18. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 124 centers.

19. Pilot study: External surface contamination of gemcitabine and 5-fluorouracil on drug packaging.

20. Ovarian cancer classification and prognosis assessment model based on prognostic target genes in key microRNA‐target gene networks.

21. Performance Qualification of Automatic System for Antineoplastic Preparation.

22. Residual contamination in antineoplastic drug packaging.

23. Perception, knowledge, practices and training regarding the risk of exposure to antineoplastic drugs in three French compounding units.

24. Laccase-Assisted Degradation of Anticancer Drug Etoposide: By-Products and Cytotoxicity.

25. Biological response to the continuous occupational exposure to antineoplastic drugs and radionuclides.

26. Wipe sampling of antineoplastic drugs from workplace surfaces: A review of analytical methods and recommendations

27. CCL2 and Lactate from Chemotherapeutics-Treated Fibroblasts Drive Malignant Traits by Metabolic Rewiring in Low-Migrating Breast Cancer Cell Lines

30. The renal damage and mechanisms relevant to antitumoral drugs

31. Theoretical rejection of fifty-four antineoplastic drugs by different nanofiltration membranes.

32. Knowledge and practices about safe handling regarding the risk of exposure to antineoplastic drugs for caregivers in compounding units and in operating rooms performing HIPEC/PIPAC.

33. Comparing different robots available in the European market for the preparation of injectable chemotherapy and recommendations to users.

34. The Comet Assay as a Tool in Human Biomonitoring Studies of Environmental and Occupational Exposure to Chemicals—A Systematic Scoping Review

35. Proposals of guidance values for surface contamination by antineoplastic drugs based on long term monitoring in Czech and Slovak hospitals and pharmacies

36. Biological functions and research progress of eIF4E.

37. Evaluation of long-term data on surface contamination by antineoplastic drugs in pharmacies.

38. Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units.

39. Pretreatment of ellagic acid protects ifosfamide-induced acute nephrotoxicity in rat kidneys: A mitochondrial, histopathological and oxidative stress approaches

40. Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs)

41. Profile of judicialization in access to antineoplastic drugs and their costs: a cross-sectional, descriptive study based on a set of all lawsuits filed between 2016 and 2018 in a state in the Northeast Region of Brazil

42. Improvement of the In Vitro Cytotoxic Effect on HT-29 Colon Cancer Cells by Combining 5-Fluorouacil and Fluphenazine with Green, Red or Brown Propolis.

43. The Hypothesis of a New Extrachromosomal Approach to Cancer Treatment.

44. Chromosomal damage in occupationally exposed health professionals assessed by two cytogenetic methods.

45. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers.

46. 静脉用药集中调配中心审方系统改进前后抗肿瘤药不合理医嘱对比分析.

47. Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor.

48. Study on the Use of Ozone Water as a Chemical Decontamination Agent for Antineoplastic Drugs in Clinical Settings.

49. SATISFACTION WITH NURSING CARE OF ONCOLOGY PATIENTS ON OUTPATIENT ANTINEOPLASTIC DRUGS

50. A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5

Catalog

Books, media, physical & digital resources